Bioantibody
Latest round
- Series A
Last raised
- Jan 2023
Total raised
- $15M
Investors
- 4
About Bioantibody
Established in 2019 and based in Nanjing, China, Bioantibody is a biopharmaceutical company that focuses on in vitro diagnostic ingredients, in vitro diagnostic reagents and the early discovery of therapeutic antibody drugs. The company has independently developed antigenic antibody materials for more than 60 diagnostic targets, with a total of more than 1200 customers as of 2023. The company's main business is the development, production and sale of in vitro diagnostic materials and early detection of therapeutic antibodies. The company's self-developed antibody products include monkeypox ingredients, COVID-19, infectious disease, oncology indicators, cardiovascular, inflammation, kidney injury and diabetes products.
Who invested in Bioantibody
4 investors across 1 round
See all investors in Bioantibody
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Jan 12, 2023
Amount
$15M
Investors
Questions about Bioantibody
Who invested in Bioantibody?
Bioantibody has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Bioantibody raised?
Bioantibody has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Bioantibody last raise money?
Bioantibody's most recent round on record is a Series A, in Jan 2023.
What does Bioantibody do?
Established in 2019 and based in Nanjing, China, Bioantibody is a biopharmaceutical company that focuses on in vitro diagnostic ingredients, in vitro diagnostic reagents and the early discovery of therapeutic antibody drugs.
Where is Bioantibody headquartered?
Bioantibody is headquartered in Nanjing, China.
Which VCs invest in companies like Bioantibody?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Bioantibody's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Bioantibody? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.